Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2328-2341

  Chaudhary, P ^a   Thamake, S I ^a,b   Shetty, P ^a,c   Vishwanatha, J K ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b RadioMedix Inc   (United States)

^c SDM COLLEGE OF MEDICAL SCIENCES AND HOSPITAL   (India)

Author keywords

Annexin A2; epidermal growth factor receptor; Herceptin resistant breast cancer; migration; proliferation; triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOCORTIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASSAY; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CLONOGENIC ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; HERCEPTIN RESISTANT BREAST CANCER; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INCUBATION TIME; INTERNALIZATION; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; WOUND HEALING ASSAY; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOLOGY; MCF 7 CELL LINE; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANNEXIN A2; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; SIGNAL TRANSDUCTION; TRASTUZUMAB; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84927567851     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.542     Document Type: Article

References (50)

1. Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, Gupta NP, Trevino L, Vishwanatha JK (2003) Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer 2: 34.
2. Bharadwaj A, Bydoun M, Holloway R, Waisman D (2013) Annexin A2 heterotetramer: structure and function. Int J Mol Sci 14: 6259-6305.
3. Biener Y, Feinstein R, Mayak M, Kaburagi Y, Kadowaki T, Zick Y (1996) Annexin II is a novel player in insulin signal transduction. Possible association between annexin II phosphorylation and insulin receptor internalization. J Biol Chem 271: 29489-29496.
4. Chuthapisith S, Bean BE, Cowley G, Eremin JM, Samphao S, Layfield R, Kerr ID, Wiseman J, El-Sheemy M, Sreenivasan T, Eremin O (2009) Annexins in human breast cancer: possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer 45: 1274-1281.
5. Chuthapisith S, Layfield R, Kerr ID, Hughes C, Eremin O (2007) Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30: 1545-1551.
6. de Graauw M, Cao L, Winkel L, van Miltenburg MH, le Dévédec SE, Klop M, Yan K, Pont C, Rogkoti VM, Tijsma A, Chaudhuri A, Lalai R, Price L, Verbeek F, van de Water B (2014) Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation. Oncogene 33: 2610-2619.
7. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
8. D'Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL, Roodman GD (2012) Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 119: 1888-1896.
9. Eccles SA (2011) The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 55: 685-696.
10. Flood EC, Hajjar KA (2011) The annexin A2 system and vascular homeostasis. Vascul Pharmacol 54: 59-67.
11. Grewal T, Enrich C (2009) Annexins-modulators of EGF receptor signalling and trafficking. Cell Signal 21: 847-858.
12. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82: 331-371.
13. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8: 258.
14. Hurvitz SA, Finn RS (2009) What's positive about 'triple-negative' breast cancer? Future Oncol 5: 1015-1025.
15. Jeon YR, Kim SY, Lee EJ, Kim YN, Noh DY, Park SY, Moon A (2013) Identification of annexin II as a novel secretory biomarker for breast cancer. Proteomics 13: 3145-3156.
16. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-53.
17. Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, Frangioni JV, Jacoby DB (2010) Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem 285: 4366-4374.
18. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN (2006) Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethylisothiocyanate and curcumin. Carcinogenesis 27: 475-482.
19. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS (1997) Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 17: 4406-4418.
20. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
21. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA (2004) Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 113: 38-48.
22. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136: 331-345.
23. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
24. Ortiz-Zapater E, Peiró S, Roda O, Corominas JM, Aguilar S, Ampurdanés C, Real FX, Navarro P (2007) Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol 170: 1573-1584.
25. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247.
26. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
27. Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res 15: 7479-7491.
28. Rescher U, Gerke V (2004) Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 117: 2631-2639.
29. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
30. Sampaio C, Dance M, Montagner A, Edouard T, Malet N, Perret B, Yart A, Salles JP, Raynal P (2008) Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition. Mol Cell Biol 28: 587-600.
31. Sharma MC, Sharma M (2007) The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 13: 3568-3575.
32. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81: 146-156.
33. Sharma M, Blackman MR, Sharma MC (2012) Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 92: 175-184.
34. Sharma M, Ownbey RT, Sharma MC (2010) Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88: 278-286.
35. Shetty PK, Thamake SI, Biswas S, Johansson SL, Vishwanatha JK (2012) Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. PLoS One 7: e44299.
36. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
37. Stevens KN, Vachon CM, Couch FJ (2013) Genetic susceptibility to triple-negative breast cancer. Cancer Res 73: 2025-2030.
38. Tuszynski GP, Sharma MR, Rothman VL, Sharma MC (2002) Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 64: 448-462.
39. Valapala M, Vishwanatha JK (2011) Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem 286: 30911-30925.
40. Valapala M, Thamake SI, Vishwanatha JK (2011a) A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci 124: 1453-1464.
41. Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM (1993) Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14: 2575-2579.
42. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
43. Warfel NA, Niederst M, Newton AC (2011) Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286: 39122-39129.
44. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
45. Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks N, Roche S, Payrastre B, Chap H, Raynal P (2001) A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogenactivated protein kinases by epidermal growth factor. J Biol Chem 276: 8856-8864.
46. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12: 537-544.
47. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R (2009) Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 8: 5041-5047.
48. Zhang Y, Zhou ZH, Bugge TH, Wahl LM (2007) Urokinase-type plasminogen activator stimulation of monocyte matrix metalloproteinase-1 production is mediated by plasmin-dependent signaling through annexin A2 and inhibited by inactive plasmin. J Immunol 179: 3297-3304.
49. Zhang X, Liu S, Guo C, Zong J, Sun MZ (2012) The association of annexin A2 and cancers. Clin Transl Oncol 14: 634-640.
50. Zhao WQ, Chen GH, Chen H, Pascale A, Ravindranath L, Quon MJ, Alkon DL (2003) Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. J Biol Chem 278: 4205-4215.